LAUSR

Galectin‐3 is a member of the lectin family encoded by the LGALS3 gene on chromosome 14. It is secreted by a wide range of immune cells and mammary tumor cells. Through its activity on the tumor microenvironment, in particular on tumor‐infiltrating leukocytes, galectin‐3 improves the proliferation, survival, and colonizing ability of mammary neoplastic cells. Consequently, galectin‐3 expression in the tumor microenvironment could worsen therapeutic outcomes of breast neoplasms and become a biomarker and a therapeutic target in combined immunotherapy in breast neoplasms. There is a limited amount of information that is available on galectin‐3 in breast cancer in Africa. In this review, we analyze how galectin‐3 influences the tumor microenvironment and its potential as a biomarker and therapeutic target in breast neoplasms. We aim to emphasize the significance of investigating galectin‐3 in breast neoplasms in Africa based on the results of studies conducted elsewhere.